QC-01-175 was shown to degrade Tau at concentrations ranging from 100 nM to 1 μM in patient-derived neuronal cell models, including the Tau-A152T variant from a PSP patient and the Tau-P301L variant obtained from a behavioural-variant FTD patient [42]. This evidence concerns the gene MAPT and frontotemporal dementia.